Tumor, Colorectal, Tumor Gastric
Conditions
Brief summary
The goal of this study is to learn about the safety and tolerance of autologous TSA-DC cell and evaluate the efficacy and feasibility of the cell therapy compared to the patients' past standard regimen. 20 gastrointestinal solid tumors subjects failed from at least one systemic therapy will be enrolled into the trial and receive a succession of treatment of TSA-DC vaccine.
Detailed description
20 gastrointestinal solid tumor subjects failed from at least one systemic therapy will be enrolled into the trial .Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1, 3, 5, 11,17,23,35,47. Before the first cell infusion, the subjects should undergo a non-myeloablative chemotherapy regimen of Cyclophosphamide 300mg/m2 iv. Radiologic tumor assessment will be repeated every 8 weeks during treatment, until time of progression. Treatment will continue until disease progression, intolerance of toxic , withdrawal from the study, study completion, or study termination.
Interventions
BIOLOGICALTumor Specific Antigen-loaded Dendritic Cells
Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1,3,5,11,17,23,35,47.
DRUGCyclophosphamide
300 mg/m2 by vein before the first cell infusion.
Sponsors
Fujian Cancer Hospital
BGI, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Be ≥18 and ≤75,no gender based; 2. Expression of HLA-A0201/1101/2402; 3. Histopathologic documentation of gastrointestinal solid tumors(stomach cancer or colorectal cancer ) concurrent with the diagnosis of metastatic disease, and the tumor is Measurable; 4. Patients must have adequate tissue (fresh or paraffin block) for DNA extraction, which is used for gene sequencing, and prognoses the tumor specific antigen in turn,can predict to have new tumor antigens with high affinity for MHC molecules; 5. Failure in conventional treatment， or though benefit from chemotherapy the patient can't tolerant subjectively; 6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 and an anticipate life expectancy of at least three months,be cooperate to adverse reactions monitoring and therapeutic evaluation of the treatment; 7. Participants of child-bearing potential must agree to use adequate contraceptive methods up to 12 months after the pretreatment; 8. Serology：Seronegative for HIV antibody,seronegative for hepatitis C antibody. Hematology：Absolute neutrophil count ≥ 1000/mm(3) without the support of filgrastim ,WBC ≥ 3000/mm(3)，lymphocyte count ≥ 800/mm(3)，Platelet count ≥ 100,000/mm(3)，Hemoglobin ≥ 9.0 g/dl Chemistry：Serum ALT/AST ≤ 2.5 times the upper limit of normal，Serum Creatinine ≤1.6 mg/dl，Total bilirubin \< 1.5 mg/dl, except in patients with Gilbert s Syndrome who must have a total bilirubin \< 3.0 mg/dl; 9. Patients or their legal representatives are willing and able to understand and written informed consent form for the trial;
Exclusion criteria
1. Is pregnant or breastfeeding,or expecting to conceive; 2. Have a history of severe immediate hypersensitivity reaction to any of the agents used in this study. 3. Suffered grade 3-4 major organ immune-related adverse events after anti-PD1/PDL1 antibody treatment. 4. Once received allogeneic organ transplantation (including bone marrow transplantation and peripheral stem cell transplantation, except for corneal transplantation); 5. Have clinical symptoms of central nervous system metastases; 6. Have used a large number of glucocorticoids or other immunosuppressive agents within 4 weeks; 7. Have any active autoimmune disease ; 8. Be in active infection or undergo an unknown cause fever\> 38.5 ℃ during screening or before the first administration(except tumor fever which evaluated by the researchers have no effect to enrollment ); 9. Received chemotherapy or small molecule targeted drug therapy in 4 weeks prior to chemotherapy pretreatment; 10. Received any antibody drug therapy (including PD-1 and CTLA-4) within 6 weeks before the treatment period; 11. Severe liver and kidney dysfunction or uncontrollable diabetes, hypertension and other chronic systemic diseases; severe coagulation disorders, mental illness, cardiopulmonary disease，hydrothorax or ascites;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| safety endpoint | one year | All the local or systemic reactions, adverse events and serious adverse events that occurred between the first and the second TSA-DC administration. |
| Overall Response Rate | one year | Percentage of cases whose tumor shrinks to a certain extent and remains for a certain period of time. |
| Proportion of the number of cases that has produced tumor-specific antigen-specific T cells in peripheral blood. | one year | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival(PFS) | one year | The time from entering the trial till the subject has been diagnosed with progression of disease or died. |
| Secondary safety endpoint | one year | All local or systemic reactions, adverse events and serious adverse events that occurred from entering the trial until 30 days after the last treatment; |
| Quality score of life improvement | one year | Evaluated by the questionnaire of life improvement quality collected from the screening to treatment periods. |
| rate of 12-month survival | one year | Percentage of cases with 12 months survival after initiation of treatment in all the subjects; |
| Six month DCR(CRR+PRR+SDR) | 6 month | Percentage of cases with no progression (CR + PR + SD) in 6 months after initiation of treatment; |
| Duration of Response(DOR) | one year | The time from the first tumor evaluation of remission(CR + PR ) till the first assessment of PD or the end the study. |
Contacts
Primary ContactYu Chen, Doctor
Outcome results
None listed